However, the risk for thyroid cancer was significantly higher within the first year after GLP-1RA initiation and was amplified in the overall as-treated analysis that censored patients when therapy was discontinued or another medication was added. The research team indicates this could be a sign that GLP-1 users are being screened for thyroid cancer at a higher rate than other diabetes drugs, resulting in a spike in diagnoses in the first year of taking the drug
Their partnershipespecially when paired with zincdelivers holistic support for skin radiance, immune strength, and overall vigour
doi: 10.1007/s00395-010-0114-3 16 TaoASongJLanTXuXKvietysPKaoRet al
Chavarro JE, Toth TL, Wright DL, Meeker JD, Hauser R
*Correspondence: Alessandro Armuzzi, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Lilly has now announced its intention to seek approval through a BLA